Loading clinical trials...
Loading clinical trials...
A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Participated in Either EFC18418 or EFC18419 Clinical Studies
Conditions
Interventions
Itepekimab (SAR440340)
Placebo
Locations
4
United States
Velocity Clinical Research - San Diego- Site Number : 8402041
La Mesa, California, United States
Investigational Site Number : 0362001
Spearwood, Western Australia, Australia
Investigational Site Number : 1562001
Beijing, China
Investigational Site Number : 8261004
Bradford, United Kingdom
Start Date
March 12, 2026
Primary Completion Date
December 12, 2028
Completion Date
December 12, 2028
Last Updated
April 13, 2026
NCT06914908
NCT05246267
NCT07125586
NCT06118554
NCT05708300
NCT06069310
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions